189 related articles for article (PubMed ID: 21534873)
21. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Takeuchi M; Koseki M; Uryu H
Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Scheuring U; Pfeifer H; Binckebanck A; Käbisch A; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Oct; 17(10):1919-24. PubMed ID: 14513038
[TBL] [Abstract][Full Text] [Related]
23. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
24. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
25. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
Hato T; Yamanouchi J; Tamura T; Hojo N; Niiya Y; Kohno M; Bando S; Yakushijin Y; Takada K; Sakai I; Yasukawa M; Fujita S
Int J Hematol; 2004 Jul; 80(1):62-6. PubMed ID: 15293570
[TBL] [Abstract][Full Text] [Related]
26. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Vega-Ruiz A; O'Brien S; Cortes J; Kebriaei P; Thomas D; Kantarjian H; Ravandi F
Leuk Res; 2008 Sep; 32(9):1468-71. PubMed ID: 18355919
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Milone JH; Enrico A
Leuk Lymphoma; 2009 Dec; 50 Suppl 2():9-15. PubMed ID: 20017606
[TBL] [Abstract][Full Text] [Related]
28. [A patient with acute Philadelphia-chromosome-positive mixed phenotype leukemia developing ecthyma gangrenosum while undergoing combined imatinib mesylate chemotherapy].
Suzuki K; Sekine T
Kansenshogaku Zasshi; 2009 Nov; 83(6):669-72. PubMed ID: 20034323
[TBL] [Abstract][Full Text] [Related]
29. Pneumatosis intestinalis and imatinib mesylate.
O'Rafferty C; McElligott F; Storey L; O'Marcaigh A; Smith O
Ann Hematol; 2014 Oct; 93(10):1783-4. PubMed ID: 24647683
[No Abstract] [Full Text] [Related]
30. [Clinical study of 32 patients with adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Chen XY; Zheng YL; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1567-71. PubMed ID: 25543476
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
32. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
33. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.
Vignetti M; Fazi P; Cimino G; Martinelli G; Di Raimondo F; Ferrara F; Meloni G; Ambrosetti A; Quarta G; Pagano L; Rege-Cambrin G; Elia L; Bertieri R; Annino L; Foà R; Baccarani M; Mandelli F
Blood; 2007 May; 109(9):3676-8. PubMed ID: 17213285
[TBL] [Abstract][Full Text] [Related]
34. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
36. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
37. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.
Sanchez-Gonzalez B; Pascual-Ramirez JC; Fernandez-Abellan P; Belinchon-Romero I; Rivas C; Vegara-Aguilera G
Blood; 2003 Mar; 101(6):2446. PubMed ID: 12609964
[No Abstract] [Full Text] [Related]
38. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
39. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
Matsue K; Matsuo K; Fujiwara H; Iwama K; Hayama BY; Kimura S; Yamakura M; Takeuch M
Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163
[No Abstract] [Full Text] [Related]
40. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Dann EJ; Fineman R; Rowe JM
J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
